Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Statins zinc salt-containing blood fat-reducing composite

A composition and a blood lipid-lowering technology, applied in the field of medicine, can solve the problems of high production cost, poor stability, complicated calcium salt production process, etc., and achieve the effect of significant curative effect and cholesterol reduction.

Inactive Publication Date: 2012-02-22
FUKANGREN BIO PHARMA
View PDF2 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the poor stability of amorphous rosuvastatin, currently marketed rosuvastatin exists in the form of calcium salt, but the production process of rosuvastatin calcium salt is relatively complicated and the production cost is relatively high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Statins zinc salt-containing blood fat-reducing composite
  • Statins zinc salt-containing blood fat-reducing composite
  • Statins zinc salt-containing blood fat-reducing composite

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1 Compound Rosuvastatin Zinc Nicotinic Acid Tablets

[0018]

[0019] Preparation:

[0020] 1. Add the prescribed amount of Tween 80 to purified water at 50°C, stir well to dissolve, add hydroxypropyl cellulose to hydrate it, and form a binder.

[0021] 2. The prescribed amount of rosuvastatin zinc, calcium carbonate, microcrystalline cellulose, starch 1500, and croscarmellose sodium are fully mixed uniformly by equal amount addition method.

[0022] 3. Add the binder soft material obtained in step 1 to the mixed powder obtained in step 2, and granulate with an 18-mesh sieve.

[0023] 4. Dry the granules obtained in step 3, and control the moisture content to be no more than 2.0%.

[0024] 5. Add nicotinic acid, microcrystalline cellulose, croscarmellose sodium, and silicon dioxide to the granules obtained in step 4 and mix well. Pass through a 24-mesh sieve.

[0025] 6. Add magnesium stearate to the mixed granules obtained in step 5, mix well, and press ...

Embodiment 2

[0026] Example 2 Compound Rosuvastatin Zinc Fenofibrate Tablets

[0027]

[0028] Preparation:

[0029] 1. Add the prescribed amount of Tween 80 to purified water at 50°C, stir well to dissolve, add hydroxypropyl cellulose to hydrate it, and form a binder.

[0030] 2. The prescribed amount of rosuvastatin zinc, calcium carbonate, microcrystalline cellulose, starch 1500, and croscarmellose sodium are fully mixed uniformly by equal amount addition method.

[0031] 3. Add the binder soft material obtained in step 1 to the mixed powder obtained in step 2, and granulate with an 18-mesh sieve.

[0032] 4. Dry the granules obtained in step 3, and control the moisture content to be no more than 2.0%.

[0033] 5. Add fenofibrate, microcrystalline cellulose, croscarmellose sodium, and silicon dioxide to the granules obtained in step 4 and mix well. Pass through a 24-mesh sieve.

[0034] 6. Add magnesium stearate to the mixed granules obtained in step 5, mix well, and press into t...

Embodiment 3

[0035] Example 3 Compound Rosuvastatin Ezetimibe Tablets

[0036]

[0037] Preparation:

[0038] 1. Add the prescribed amount of Tween 80 to purified water at 50°C, stir well to dissolve, add hydroxypropyl cellulose to hydrate it, and form a binder.

[0039] 2. Fully mix the prescription amount of rosuvastatin zinc, calcium phosphate, pregelatinized starch, starch 1500, and methyl cellulose with the method of equal volume addition.

[0040] 3. Add the binder soft material obtained in step 1 to the mixed powder obtained in step 2, and granulate with an 18-mesh sieve.

[0041] 4. Dry the granules obtained in step 3, and control the moisture content to be no more than 2.0%.

[0042] 5. Add ezetimibe, pregelatinized starch, methylcellulose and silicon dioxide to the granules obtained in step 4 and mix well. Pass through a 24-mesh sieve.

[0043] 6. Add magnesium stearate to the mixed granules obtained in step 5, mix well, and press into tablets to obtain final product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an oral drug composite for reducing the blood fat, in particular to a drug composite which takes any 1-2 of statins zinc salt and nicotinic acidniacin blood fat reducing medicine or fibrates blood fat reducing medicine or cholesterol restraining and absorbing medicine as active ingredients, the preparation of the drug composite, and the use of the drug composite. The drug composite takes the statins zinc salt and the nicotinic acidniacin blood fat reducing medicine or the fibrates blood fat reducing medicine or the cholesterol restraining and absorbing medicine as the active ingredients and takes the corresponding ingredients as the drug auxiliary materials. The oral preparation which is prepared according to the technology and the method of the patent description comprises granular formulation, conventional tablet, chewable tablet, dispersible tablet, orally disintegrating tablet, buccal tablet, capsule, soft capsule, pill, sustained release tablet, sustained release capsule and the like. The oral drug composite is quick and durable in effect, and is convenient to take, thereby being used for treating various hyperlipemias.

Description

technical field [0001] The invention relates to a blood lipid-lowering composition containing zinc salt of statins, which belongs to the technical field of medicine. Background technique [0002] Hyperlipidemia refers to high cholesterol (TC) and / or triglyceride (TG) or low high-density lipoprotein cholesterol (HDL-C) in the blood. The damage to the body of the disease is hidden, gradual, progressive and systemic. sexual. Its direct damage is to accelerate systemic atherosclerosis, because vital organs of the whole body rely on arterial blood supply and oxygen supply. Once the arteries are blocked by atherosclerotic plaques, serious consequences will result. Renal failure caused by arteriosclerosis is closely related to hyperlipidemia. A large number of research data show that hyperlipidemia is an independent and important risk factor for stroke, coronary heart disease, myocardial infarction, and sudden cardiac death. In recent years, a variety of blood lipid-lowering dru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/505A61K31/455A61K31/397A61K31/216A61P3/06
Inventor 不公告发明人
Owner FUKANGREN BIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com